Abstract
Protein kinase C-theta (PKCθ) is a key enzyme in T lymphocytes, where it plays an important role in signal transduction downstream of the activated T cell antigen receptor (TCR) and the CD28 costimulatory receptor. Interest in PKCθ as a potential drug target has increased following recent findings that PKCθ is essential for harmful inflammatory responses mediated by Th2 (allergies) and Th17 (autoimmunity) cells as well as for graft-versus-host disease (GvHD) and allograft rejection, but is dispensable for beneficial responses such as antiviral immunity and graft-versus-leukemia (GvL) response. TCR/CD28 engagement triggers the translocation of the cytosolic PKCθ to the plasma membrane (PM), where it localizes at the center of the immunological synapse (IS), which forms at the contact site between an antigen-specific T cell and antigen-presenting cells (APC). However, the molecular basis for this unique localization, and whether it is required for its proper function have remained unresolved issues until recently. Our recent study resolved these questions by demonstrating that the unique V3 (hinge) domain of PKCθ and, more specifically, a proline-rich motif within this domain, is essential and sufficient for its localization at the IS, where it is anchored to the cytoplasmic tail of CD28 via an indirect mechanism involving Lck protein tyrosine kinase (PTK) as an intermediate. Importantly, the association of PKCθ with CD28 is essential not only for IS localization, but also for PKCθ-mediated activation of downstream signaling pathways, including the transcription factors NF-κB and NF-AT, which are essential for productive T cell activation. Hence, interference with formation of the PKCθ-Lck-CD28 complex provides a promising basis for the design of novel, clinically useful allosteric PKCθ inhibitors. An additional recent study demonstrated that TCR triggering activates the germinal center kinase (GSK)-like kinase (GLK) and induces its association with the SLP-76 adaptor at the IS, where GLK phosphorylates the activation loop of PKCθ, converting it into an active enzyme. This recent progress, coupled with the need to study the biology of PKCθ in human T cells, is likely to facilitate the development of PKCθ-based therapeutic modalities for T cell-mediated diseases.
INTRODUCTION
Protein kinase C-theta (PKCθ) is a key regulator of signal transduction in activated T cells that is linked to multiple pathways downstream of the T cell antigen receptor (TCR; Isakov and Altman, 2002). Engagement of the TCR and the resulting formation of diacylglycerol (DAG) are sufficient for promoting PKCθ recruitment to cell membranes (Monks et al., 1997, 1998). However, localization of PKCθ to the immunological synapse (IS) is entirely dependent on the concomitant ligation of the CD28 coreceptor (Huang et al., 2002). Localization of PKCθ at the center of the IS is essential for activation of signaling pathways that promote T cell-dependent immune responses against distinct antigens and pathogens. While the recruitment of PKCθ to the IS of TCR/CD28 engaged T cells has been extensively studied, information on the molecular basis for this highly selective process has been relatively scarce until recently. The present manuscript provides background information on the molecules involved in this process and describes in more detail the studies that clarified a new mechanism by which PKCθ is being recruited to the center of the IS and is essential for the induction of PKCθ-dependent activation signals.
THE PKC FAMILY
Protein kinase C was discovered by Nishizuka and colleagues, who demonstrated a new kinase that undergoes activation by limited proteolysis (Inoue et al., 1977), or by translocation to the plasma membrane (PM), where it associates with specific cofactors (Takai et al., 1979). The membrane-associated PKC-activating factor turned to be DAG (Kishimoto et al., 1980). DAG, together with inositol 1,4,5-trisphophate (IP3), are products of phospholipase C-mediated hydrolysis of the membrane phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2; Berridge and Irvine, 1984; Nishizuka, 1984). These two second messengers transduce signals from a plethora of activated receptors: the hydrophobic DAG remains bound to the cell membrane where, in addition to PKC, it activates effector molecules such as RasGRP, a guanine nucleotide exchange factor (GEF) for Ras (Lorenzo et al., 2000), while the hydrophilic IP3 diffuses through the cytosol and binds IP3-receptors, which function as ligand-gated Ca2+ channels in the endoplasmic reticulum (ER), thereby triggering the release of free Ca2+ ions into the cytoplasm (Takai et al., 1979; Khan et al., 1992; Bourguignon et al., 1994). The utilization of phorbol esters, which mimic the activity of DAG, together with Ca2+ ionophores, demonstrated that PKC also plays an essential role in the induction of T lymphocyte proliferation (Truneh et al., 1985; Isakov and Altman, 1987) and reactivation of effector cytotoxic T cells (Isakov and Altman, 1985; Isakov et al., 1987).
Protein kinase C enzymes transduce a myriad of signals from a large number of cell surface receptors that are coupled to phospholipase C and phospholipid hydrolysis. They regulate the function of effector molecules by phosphorylating specific serine and threonine residues. The PKC family includes 10 structurally and functionally related isoforms (for more details, see the first review by Pfeifhofer-Obermair et al., 2012), grouped into three subfamilies based on the composition of their regulatory domains and their respective cofactor requirements (Newton, 1995; Mellor and Parker, 1998). The first subfamily includes conventional PKCs (cPKC; α, βI, βII, γ) that are regulated via two DAG-binding C1 domains organized in tandem near the cPKC amino terminus (Hurley et al., 1997; Johnson et al., 2000; Ho et al., 2001) and an adjacent Ca2+ and phospholipid-binding C2 domain (Nalefski and Falke, 1996; Johnson et al., 2000). The second group includes novel PKCs (nPKC; δ, ε, η, θ) that are DAG-dependent, but Ca2+ and phospholipid independent for their activity. The third group includes atypical PKCs (aPKC: ζ, λ/ι) that are DAG-, Ca2+-, and phospholipid-independent. While PKC enzymes are involved in metabolic processes in different cell types, many studies implicate PKC enzymes in signal transduction networks that convert environmental cues into cellular actions (Rosse et al., 2010). Six of the PKC isoforms, including PKCα, δ, ε, η, θ, and ζ are expressed at varying amounts in T cells (Meller et al., 1999). Immunological studies using different genetic models and pharmacological drugs indicated that distinct PKC isoforms are required for different aspects of the activation and effector functions of T cells. The results suggest that distinct PKC isoforms may serve as drug targets for different T cell mediated adaptive immune responses (Baier and Wagner, 2009).
PROTEIN KINASE C-THETA
Protein kinase C-theta is a Ca2+-independent nPKC isoform exhibiting a relatively selective pattern of tissue distribution, with predominant expression in T lymphocytes (Baier et al., 1993; Meller et al., 1999), platelets (Chang et al., 1993; Meller et al., 1998; Cohen et al., 2009), and skeletal muscle (Osada et al., 1992; Chang et al., 1993). It has a unique ability to translocate to the center of the IS of activated T cells (Monks et al., 1997, 1998) where its full activation requires the integration of TCR and CD28 costimulatory signals (Huang et al., 2002; Tseng et al., 2008; Yokosuka et al., 2008). Engagement of the TCR and the CD28 coreceptor initiates a series of PKCθ-dependent signaling events leading to activation of transcription factors, including NF-κB, AP-1, and NF-AT, which are critical for T cell activation, proliferation and differentiation (Baier-Bitterlich et al., 1996; Coudronniere et al., 2000; Dienz et al., 2000; Lin et al., 2000; Sun et al., 2000; Pfeifhofer et al., 2003). Under certain activation conditions, PKCθ can translocate to the nucleus where it directly associates with chromatin and is involved in the regulation of microRNAs and T cell-specific inducible gene expression program (Sutcliffe et al., 2011). The exact mechanism by which the membrane-bound PKCθ delivers signals to the nucleus has not been fully resolved but studies provided information on a number of effector molecules that operate along this pathway in activated T cells. These studies demonstrated that PKCθ-mediated regulation of NF-κB activity involves the multisubunit inhibitor of κB (IκB) kinase (IKK) complex (Coudronniere et al., 2000; Dienz et al., 2000; Khoshnan et al., 2000; Lin et al., 2000; Bauer et al., 2001).
An important upstream effector in the NF-κB signaling pathway is IκBα, which binds NF-κB in the cytoplasm of resting T cells and mask its nuclear localization signal (NLS), thereby preventing NF-κB translocation to the nucleus (Mercurio et al., 1997; Regnier et al., 1997; Jacobs and Harrison, 1998). IKK-mediated phosphorylation of IκBα signals the protein for degradation (Karin, 1999), exposes the NF-κB NLS and promotes NF-κB translocation to the nucleus and the induction of NF-κB-mediated gene transcription. T cells from PKCθ-deficient (Prkcq– / –) mice fail to respond to TCR stimulation with degradation of IκBα (Sun et al., 2000), supporting the model whereby PKCθ regulates NF-κB activity through its effect on IKK-IκBα. Some of the effector molecules that link PKCθ to IKK have been identified and include the PKCθ substrate protein, caspase activation and recruitment domain (CARD) and membrane-associated guanylate kinase (MAGUK) domain-containing protein-1 (CARMA1). This scaffold protein is primarily expressed in lymphocytes (Bertin et al., 2001; Hara et al., 2003), where it links PKCθ to NF-κB activation in T cells (Ruland et al., 2001, 2003; Ruefli-Brasse et al., 2003; Xue et al., 2003). Phosphorylation of CARMA1 by PKCθ in TCR/CD28-stimulated T cells, promotes CARMA1 association with the B-cell lymphoma/leukemia 10 (Bcl10) and mucosa-associated lymphoid tissue 1 (MALT1) proteins (Matsumoto et al., 2005; Sommer et al., 2005) leading to recruitment of the trimolecular complex to the IS (Gaide et al., 2002; Che et al., 2004; Hara et al., 2004) and activation of the IKK complex (McAllister-Lucas et al., 2001). Furthermore, overexpression of CARMA1, Bcl10, and MALT1 in T cells, followed by TCR/CD28 stimulation, resulted in the formation of a CARMA1-Bcl10-MALT1 trimolecular complex, where all three proteins were required for maximal activation of NF-κB (McAllister-Lucas et al., 2001; Ruland et al., 2001). It should be noted that in some studies (Khoshnan et al., 2000), but not others (Lin et al., 2000), PKCθ was found to directly associate with members of the IKK complex, particularly IKKβ, suggesting the potential existence of an additional linear route from PKCθ to NF-κB. The transcription factor AP-1, similar to NF-κB, is a primary physiological target of PKCθ (Baier-Bitterlich et al., 1996; Li et al., 2004), while regulation of the NF-AT transcription factor requires cooperation between PKCθ and calcineurin, a Ca2+-dependent serine/threonine phosphatase (Pfeifhofer et al., 2003). All three PKCθ-regulated transcription factors have corresponding binding sites on the IL-2 gene promoter, and their binding to the IL-2 gene is essential for optimal IL-2 response (Isakov and Altman, 2002).
While PKCθ-mediated regulation of NF-κB activity in TCR/CD28-stimulated T cells has been studied in great detail, PKCθ is also involved in the regulation of additional cellular functions, and physically associates with additional binding partners. Besides CARMA1, PKCθ physically associate with 14-3-3τ (Meller et al., 1996), Cbl (Liu et al., 1999), Fyn (Ron et al., 1999), Lck (Liu et al., 2000), AKT (Bauer et al., 2001), moesin (Pietromonaco et al., 1998), PICOT (Witte et al., 2000), and the HIV nef protein (Smith et al., 1996). Some of these molecules (i.e., Lck) phosphorylate PKCθ and may affect its activity and/or subcellular distribution, while others, which serve as substrates for PKCθ (i.e., Cbl, 14-3-3τ and moesin) may regulate cellular functions, such as cytoskeletal reorganization.
DIFFERENTIAL REQUIREMENTS FOR PKCθ BY DISTINCT T CELL SUBPOPULATIONS
Initial characterization of PKCθ-deficient T cells suggested the involvement of PKCθ in cellular responses leading to T cell activation, proliferation, and cytokine production (Sun et al., 2000; Pfeifhofer et al., 2003; Anderson et al., 2006). Subsequent in vitro and in vivo investigations and the analysis of Prkcq– / – mice in different disease models demonstrated differential requirements for PKCθ by distinct T cell subpopulations and during the induction of selected types of immune responses. Thus, PKCθ was found to be essential for the induction of Th2-type immune responses to allergens or helminth infection (Marsland et al., 2004; Salek-Ardakani et al., 2004) and the induction of Th17-mediated experimental autoimmune encephalomyelitis (EAE) that serves as a model of multiple sclerosis (Salek-Ardakani et al., 2005; Anderson et al., 2006; Tan et al., 2006; Marsland et al., 2007; Kwon et al., 2012), and other experimental autoimmune diseases (Anderson et al., 2006; Healy et al., 2006; Marsland et al., 2007; Chuang et al., 2011). In contrast, Th1-dependent mouse resistance to Leishmania major infection was intact in Prkcq– / – mice (Marsland et al., 2004; Ohayon et al., 2007), and PKCθ was dispensable for CTL-mediated protective antiviral responses, most likely reflecting compensation by innate immunity signals (Berg-Brown et al., 2004; Giannoni et al., 2005; Marsland et al., 2005, 2007; Valenzuela et al., 2009). Consistent with the in vivo findings, in vitro induction of CD4+ T cell polarization by optimal T cell-antigen-presenting cell (APC) coculture conditions, demonstrated a requirement for PKCθ during Th2 and Th17 cell development, and only moderate effect of PKCθ on Th1 cell development (Marsland et al., 2004; Salek-Ardakani et al., 2004, 2005). Additional studies performed in Prkcq– / – mice demonstrated the requirement for PKCθ in the induction of graft-versus-host (GvH) and alloreactive T cell-mediated immune responses (Valenzuela et al., 2009). In contrast, PKCθ-deficient T cells retained the ability to induce graft-versus-leukemia (GvL) responses in allogeneic bone marrow (BM) transplanted mice (Valenzuela et al., 2009).
Protein kinase C-theta also contributes to allograft rejection, as shown by Manicassamy et al. (2008) using an adoptive transfer model. In these studies, Rag– / – mice reconstituted with Prkcq– / – T cells were unable to reject cardiac allografts, in contrast to the acute allograft rejection observed in the wild-type T cell reconstituted Rag– / – mice. However, this was due to lack of PKCθ-regulated expression of anti-apoptotic molecules, such as Bcl-xL, which led to apoptosis of the effector T cells; transgenic expression of Bcl-xL in Prkcq– / – T cells restored their ability to reject the cardiac allografts. The rejection of cardiac allograft by Prkcq– / – mice was only slightly delayed (Manicassamy et al., 2008; Gruber et al., 2009), suggesting compensationbyother PKC isoforms. Indeed, mice lacking both PKCθ and PKCα, demonstrated a significantly delayed rejection of cardiac allografts (Gruber et al., 2009).
The overall positive role of PKCθ in the activation of effector T cells (Teff) and the promotion of adaptive immune responses raise questions about the nature of its function in regulatory T cells (Treg) that suppress Teff functions. This issue has recently been partially resolved by Zanin-Zhorov et al. (2010) who found that PKCθ mediates negative feedback on Treg functions. Furthermore, activation of Treg resulted in sequestration of PKCθ away from the IS, and inhibition of PKCθ activity (using the C20 compound) increased the suppressive activity of Treg (Zanin-Zhorov et al., 2010, 2011). In vivo studies demonstrated that Treg development in the thymus of Prkcq– / – mice is impaired leading to reduced numbers of Treg cells in the periphery (Schmidt-Supprian et al., 2004; Zanin-Zhorov et al., 2010, 2011), although activity of these mature PKCθ-deficient Treg cells was intact (Gupta et al., 2008).
THE IMMUNOLOGICAL SYNAPSE
Adaptive immune responses are dependent on the effective communication between antigen-specific T cells and APCs. At the very early phase of the activation response, T cells interact via their TCR with cognate peptide-MHC complexes on the surface of APCs and both cell types respond by redistributing their receptors/ligands to the contact area that rearranges as a platform for effective signaling (Dustin and Zhu, 2006). The IS, representing the interface between a T cell and an APC, is formed by specific protein microclustering (Yokosuka et al., 2005) and their segregation into one of two separate regions: a central core [central supramolecular activation clusters (cSMAC)], which contains the TCR and costimulatory receptors, and a peripheral region [peripheral supramolecular activation clusters (pSMAC)], which contains adhesion molecules, such as LFA-1 (Dustin, 2009). T cell surface receptor engagement triggers signaling cascades that result in the recruitment of multiple membrane-anchored and cytoplasmic effector molecules, including kinases, adaptor proteins, and cytoskeletal components, to the IS (Dustin et al., 2010). One of the most prominent proteins to be recruited to the IS of antigen-responding T cells is PKCθ, which localizes at the cSMAC (Monks et al., 1997, 1998). Additional high-resolution imaging analysis by TIRF microscopy demonstrated that PKCθ colocalizes with CD28, and demonstrated that the cSMAC is divided into two structurally and functionally distinct compartments: a central TCRhigh compartment, where signaling is terminated (Vardhana et al., 2010) and TCR-associated signaling complexes are internalized and degraded, and an outer TCRlow “ring” where PKCθ and CD28 colocalize (Yokosuka et al., 2008).
CD28
CD28 is a type 1 transmembrane glycoprotein that is constitutively expressed as a disulfide-linked homodimer on all CD4+ and CD8+ murine T cells and majority of CD4+ and CD8+ human peripheral blood T cells (Gross et al., 1990; Vallejo, 2005). The human CD28 precursor protein is 220 amino acids long (218 in mouse) and the mature protein possesses 202 amino acids (218 in mouse) due to cleavage of an amino-terminal leader sequence (18 and 19 amino acids in the human and mouse CD28, respectively). In addition, CD28 possesses a cytoplasmic tail of 41 amino acids (38 in mouse) that is critical for signal transduction and coreceptor-induced cell stimulation. Physiological activation of CD28 is mediated by one of two natural ligands expressed on the surface of APCs, CD80, and CD86, which directly associate with a conserved motif [MYPPPY (single amino-acid letter code)] in the extracellular region of CD28 (Kariv et al., 1996; Truneh et al., 1996). Engagement of CD28 provides costimulatory signals that complement or synergize with those provided by the TCR, leading to optimal activation of T cells (Thompson et al., 1989; Harding et al., 1992). CD28 engagement increases IL-2 production (Thompson et al., 1989; Jain et al., 1995; Reichert et al., 2001) and IL-2 receptor expression (Shahinian et al., 1993), and provides survival signals by upregulating the anti-apoptotic protein, Bcl-XL (Boise et al., 1993). In addition, CD28 synergizes with the TCR in providing potent signals for activation of c-Jun kinase (JNK), p38 MAP kinase, and IKK pathways (Su et al., 1994; Harhaj and Sun, 1998), and activation of the NF-κB (Michel et al., 2000; Diehn et al., 2002) AP-1 (Rincon and Flavell, 1994) and NF-AT transcription factors (Michel et al., 2000; Diehn et al., 2002).
The positive role of CD28 in T cell activation was demonstrated in CD28-deficient (Cd28– / –) T cells, in which TCR engagement in the absence of CD28 costimulation resulted in anergy and/or tolerance induction upon rechallenge with the same antigen (Appleman and Boussiotis, 2003). T cell proliferation and Th2-type cytokine secretion were also severely impaired in Cd28– / – mice or wild-type mice treated with CD28 antagonists (Green et al., 1994; Lucas et al., 1995; Rulifson et al., 1997; Schweitzer et al., 1997; Gudmundsdottir et al., 1999). Furthermore, lack of CD28-mediated costimulation led to reduced immune responses against infectious pathogens (Shahinian et al., 1993; King et al., 1996; Mittrucker et al., 2001; Compton and Farrell, 2002) and allografts (Salomon and Bluestone, 2001) and impaired GvH disease (Via et al., 1996), contact hypersensitivity (Kondo et al., 1996), and asthma (Krinzman et al., 1996).
T cell receptor engagement in the absence of CD28 costimulation induces an unbalanced signaling response in which TCR-mediated Ca2+ influx predominates. This leads to activation of calcineurin which dephosphorylates NF-AT leading to its nuclear translocation and induction of a limited set of anergy-associated genes resulting in T cell anergy (Macian et al., 2004). CD28, in contrast to the TCR, does not induce a Ca2+ response (Lyakh et al., 1997). Instead, CD28-coupled costimulatory signals induce the activation of NF-κB and AP-1, and concomitant AP-1 association with NF-AT, conditions that promote IL-2 production and rescue of the T cells from a state of anergy (Macian et al., 2004).
SIGNALING DOWNSTREAM OF CD28
CD28 delivers signals in activated T cells via its cytoplasmic tail, which has no intrinsic catalytic activity, but possesses several protein–protein interaction motifs that enable it to associate with enzymes and other effector molecules (Boise et al., 1993; see Figure 1). In resting T cells, non-phosphorylated CD28 associates with the serine/threonine protein phosphatase protein 2A (PP2A), which dissociates from CD28 upon activation induced-phosphorylation of CD28 (Chuang et al., 2000). CD28 triggering by its ligands leads to phosphorylation of tyrosine residues (Raab et al., 1995; Teng et al., 1996; King et al., 1997) in the cytoplasmic tail of CD28, creating new docking sites for different effector molecules that initiate the activation of signaling cascades, and define the costimulatory functions of CD28 (Raab et al., 1995; Andres et al., 2004; Dodson et al., 2009).
FIGURE 1
The first motif in the human CD28 cytoplasmic tail, juxtaposed to the PM, contains a Y173MNM sequence that undergoes tyrosine phosphorylation following the engagement of CD28 and serves as a binding site for the SH2 domain of p85, the regulatory subunit of the lipid kinase, phosphatidylinositol 3-kinase (PI3K; August and Dupont, 1994; Pages et al., 1994; Prasad et al., 1994; Truitt et al., 1994). The methionine residue at the +3 position confers specificity for p85 binding (Takeda et al., 2008), while the asparagine at the +2 position confers additional specificity for the SH2 domain of Grb2 and GADS (Songyang et al., 1993; Raab et al., 1995; Sanchez-Lockhart et al., 2004; Schneider et al., 1995; Harada et al., 2001). The relative concentration of PI3K, Grb2, and GADS at the vicinity of CD28 cytoplasmic tail, and the relative affinity of their SH2 domain for the phospho-Tyr173-containing motif likely determine which of the three potential binding partners interacts with the activated CD28 and, hence, the resulting functional outcome. A second, nearby motif possesses the P178RRP sequence, and serves as a binding site for the SH3 domain of IL-2-inducible T cell kinase (Itk; Marengere et al., 1997; Garcon et al., 2004). CD28-mediated activation of Itk is dependent on Lck (Gibson et al., 1996), but the actual role of Itk in CD28-induced costimulation is still controversial (Liao et al., 1997; Gibson et al., 1998; Yang and Olive, 1999; Li and Berg, 2005). A third, more distal, P190YAP motif serves as a potential docking site for several different effector molecules. These include filamin-A, an actin binding protein and a scaffold for lipid raft formation, which utilizes repeat 10 (amino acids 1158–1246) for interaction with CD28 (Tavano et al., 2006), Grb2 and GADS adaptor proteins, which bind the P190YAP motif via their SH3 domain (Okkenhaug and Rottapel, 1998; Ellis et al., 2000), and the Lck and Fyn protein tyrosine kinases (PTKs; Hutchcroft and Bierer, 1994; zur Hausen et al., 1997; Holdorf et al., 1999; Tavano et al., 2004). Both Lck and Fyn were implicated in the early phase of the CD28 signaling pathway (August et al., 1994) and coexpression studies demonstrated that the two PTKs could phosphorylate CD28, primarily on Tyr173 at the Y173MNM motif, thereby increasing the binding of p85- and Grb2-SH2 to CD28 (Raab et al., 1995). Lck and Fyn were also found to coimmunoprecipitate with CD28 from activated T cells (Hutchcroft and Bierer, 1994), where Lck interacted with the P190YAP motif via its SH3 domain (Holdorf et al., 1999; Tavano et al., 2004), and Fyn interacted with the same motif using its SH2 domain (zur Hausen et al., 1997), although other studies indicated no interaction between CD28 and Fyn (Marengere et al., 1997). While presence of the two proline residues in the P190YAP motif predicts interaction with SH3-containg proteins, binding studies demonstrated that the Lck-SH3 domain interacts with relatively low affinity (Kd > 1 μM) with peptides that contain the P190YAP motif and correspond to residues 188–202 of human CD28, or 186–196 of murine CD28, respectively (Hofinger and Sticht, 2005).
Other studies demonstrated that Tyr191 within the P190YAP motif is one of two major phosphorylation sites in CD28-stimulated Jurkat T cells, and the only tyrosine residue within the CD28 cytoplasmic tail that is essential for delivery of costimulatory signals leading to CD69 expression and synthesis and secretion of IL-2 (Sadra et al., 1999). The latter findings raise the possibility that CD28 engagement-induced phosphorylation of Tyr191 creates a new and transient binding site for SH2-containing proteins, possibly Lck, since CD28 and Lck were shown to colocalize at the cSMAC (Tavano et al., 2004; Kong et al., 2011). Binding studies provided further support for this hypothesis by showing that a CD28-derived peptide that possesses phospho-Tyr191 interacts with the Lck-SH2 domain with a relatively high affinity (Kd = 2.13 μM; Hofinger and Sticht, 2005), at the range of other SH2-ligand interactions (Bauer et al., 2004). This binding affinity is about three orders of magnitude stronger than that for the Lck-SH3 domain. High affinity binding of Lck-SH2 to P190pYAP occurs despite the difference between this sequence and the phospho-YEEI sequence predicted to be the preferred binding site of the Lck-SH2 domain (Songyang et al., 1993). More recent studies indicated that PKCθ can also interact with the cytoplasmic tail of CD28, and that this interaction involves Lck as an intermediate molecule, as discussed below.
CD28 AND THE IS
Upon binding of its ligand, B7, CD28, similar to the engaged TCR, accumulates at the cSMAC of the IS although the two receptors initiates distinct but complementary signaling pathways. The transient recruitment of CD28 to the immature IS of TCR engaged T cells is very rapid and occurs within seconds of the onset of the calcium signal (Andres et al., 2004). Engagement of the TCR in Cd28– / – T cells results in altered, diffuse pattern of distribution of PKCθ and LFA-1 at the IS, suggesting an essential role for CD28 in the initiation and stabilization of the mature IS (Huang et al., 2002; Sanchez-Lockhart et al., 2004). Furthermore, in vivo blocking of CD28 impairs the activity of effector molecules, including PKCθ (Jang et al., 2008), and inhibits T cell-dependent immune responses (Linsley and Nadler, 2009). CD28 engagement promotes a cytoskeleton-dependent recruitment of cell surface receptors (Wulfing and Davis, 1998) and signaling molecules-containing lipid rafts that support building the IS and contribute to signal transduction from IS-residing receptors (Dustin and Shaw, 1999; Viola et al., 1999).
More recent studies demonstrated that in activated T cells, CD28 is recruited coordinately with the TCR to form microclusters at the cSMAC (Yokosuka et al., 2008). Upon progression of this initial step, the CD28 and TCR segregate to two spatially distinct subregions within the cSMAC, a central TCRhigh subregion, where signaling is terminated and TCR-associated signaling complexes are internalized and degraded, and an outer TCRlow annular form that contain CD28 clusters, as well as PKCθ. CD28 and PKCθ were physically associated, as shown by PKCθ coimmunoprecipitation with CD28 from a lysate of PMA-stimulated T cells (Yokosuka et al., 2008).
PKCθ–CD28 INTERACTION AND RECRUITMENT OF PKCθ TO THE IS
T cell receptor engagement polarizes PKCθ and induce its recruitment to the IS, a response that is greatly augmented by CD28 ligation (Huang et al., 2002; Tseng et al., 2008; Yokosuka et al., 2008). Although the recruitment of PKCθ to the center of the IS (cSMAC) of is well documented, information on the molecular basis for this highly selective localization has been relatively scarce. Early studies have shown that PKCθ recruitment to the IS is indirectly dependent on the PI3K interaction motif within the CD28 cytosolic tail (Harada et al., 2001). Thus, mutation of Met173 within the mouse YMNM motif, which binds PI3K upon its tyrosine phosphorylation, resulted in decreased ability of CD28 to direct PKCθ recruitment to the cSMAC, and inhibited PKCθ-dependent activation of NF-κB to and the Il2 gene (Sanchez-Lockhart et al., 2004).
Following the recently reported PKCθ–CD28 association in PMA-stimulated T cells (Yokosuka et al., 2008), we conducted a detailed structure-function analysis of this association in TCR-stimulated T cells (Kong et al., 2011). We demonstrated that PKCθ physically associated with the cytoplasmic tail of CD28 following TCR/CD28 costimulation. Taking advantage of the fact that PKCδ, the closest relative of PKCθ, does not translocate to the IS after T cell-APC interaction (Monks et al., 1997), we compared the amino acid sequence analysis of PKCθ and PKCδ and found that they diverged significantly only in their V3 (hinge) domain, corresponding to amino acids~291–378 of human PKCθ, suggesting a potential role for this region in targeting PKCθ to the IS. Indeed, a V3-deletion mutant of PKCθ (PKCθ-∆V3) or an exchange mutant of PKCθ, in which the native V3 domain was replaced by the PKCδ V3 domain, did not coimmunoprecipitate with CD28, and failed to translocate to the IS (Kong et al., 2011) and to activate PKCθ-dependent reporter genes such as the CD28 response element (RE/AP). Conversely, the isolated V3 domain of PKCθ localized in the center of the IS and associated with CD28. Moreover, T cells recovered from mouse BM chimeras on a Prkcq– / – background reconstituted with the same PKCθ mutants failed to proliferate and produce IL-2 in response to CD3/CD28 costimulation, and their ability to upregulate CD69 or CD25 expression was reduced. Given the critical role of the V3 domain in directing the CD28 association and IS localization of PKCθ, we argued that this domain will function as a dominant negative mutant by disrupting the activation-dependent association between endogenous CD28 and PKCθ. As expected, ectopic expression of the isolated PKCθ V3 domain blocked the recruitment of endogenous PKCθ to CD28 and the IS, and severely inhibited PKCθ-dependent functions, including CD25 and CD69 upregulation, T cell proliferation and IL-2 production, and Th2 and Th17 (but not Th1) differentiation and inflammation.
Fine mapping of the PKCθ V3 domain identified an evolutionarily conserved proline-rich (PR) motif (ARPPCLPTP; corresponding to amino acid residues 328–336 of human PKCθ) within the PKCθ-V3 domain, which was required for PKCθ–CD28 association, PKCθ localization to the IS, and induction of PKCθ-mediated functions. Insertion of this motif into the V3 domain of PKCδ enabled this altered PKCδ form to translocate to the IS and activate PKCθ-dependent signal. The two internal proline residues in this motif (Pro-331 and -334) were particularly critical in this regard (Kong et al., 2011).
In trying to more precisely define the nature of the inducible PKCθ-Lck complex, we focused on the potential contribution of Lck kinase. This possibility was considered in view of previous studies demonstrating a functional relationship between CD28, PKCθ, and Lck. First, in stimulated T cells, Lck can be recruited to the tyrosine-phosphorylated distal PR motif (P190Y*AP) in the cytoplasmic tail of CD28 via its SH2 and SH3 domains, respectively (Miller et al., 2009; see Figure 2), This motif directs the colocalization of PKCθ and CD28 to the cSMAC (Yokosuka et al., 2008) and is apparently involved in additional biological functions, including the stabilization of IL-2 mRNA, reorganization of lipid rafts, and sustained autophosphorylation and activation of Lck at the IS (Holdorf et al., 2002; Sanchez-Lockhart et al., 2004; Dodson et al., 2009). Second, Lck phosphorylates and associates with PKCθ, and mutation of the major Lck phosphorylation site on PKCθ (Tyr90) inhibited PKCθ-dependent activation events in stimulated T cells (Liu et al., 2000).
FIGURE 2
Our further analysis confirmed the physical and functional CD28-Lck-PKCθ link by demonstrating that Lck function as an intermediate to recruit PKCθ to CD28 upon T cell stimulation. The Lck-SH3 domain interacted with the PR motif in the PKCθ V3 domain, while the Lck SH2 domain interacted with phospho-Tyr191 in the P190YAP motif in the CD28 cytoplasmic tail. Taken together, the above findings demonstrate a unique signaling mode of CD28 and establish the molecular basis for the specialized localization and function of PKCθ in antigen-stimulated T cells.
THE GLK-PKCθ LINK
Recent studies demonstrated that recruitment of PKCθ to the cSMAC in activated T cells is essential but not sufficient for the full activation of PKCθ and its downstream target molecules. These studies further showed that the germinal center kinase (GSK)-like kinase (GLK) also translocates to the IS of TCR-engaged T cells where it phosphorylates the activation loop of PKCθ, converting it into an active enzyme (Chuang et al., 2011). Of interest, however, despite the importance of PKCθ in the thymic development of natural regulatory T cells (nTregs; Schmidt-Supprian et al., 2004), GLK-deficient mice displayed normal nTreg development (Chuang et al., 2011). These results emphasize the important role of post-transcriptional regulation of PKCθ that occurs at several steps and involve different checkpoints at distinct sites within the activated T cell.
CONCLUSIONS AND FUTURE PERSPECTIVES
Identification and characterization of the molecular mechanism by which PKCθ associates with CD28 and colocalizes with it at the cSMAC has provided important information relevant to the mechanism by which CD28 and PKCθ contribute to signal transduction in TCR/CD28-engaged T cells. These findings also raise new questions relevant to the mechanism of interaction of CD28 and PKCθ and their specific role in the induction of distinct T cell-mediated immune responses. One obvious question relates to the mechanism by which PKCθ is sequestered away from the IS of activated Treg cells. It would be interesting to determine whether a CD28-Lck-PKCθ tri-partite complex (Kong et al., 2011) occurs in Treg cells, and determine the mechanism that enables PKCθ recruitment away from the Treg-APC contact area. A possible explanation for this process was provided by Yokosuka et al. (2010) showing that CTLA-4 competes with CD28 in recruitment to the cSMAC. In addition, it is not known whether PKCθ is involved in a second signal delivery during the costimulation of γδ T cells (Ribot et al., 2011).
Despite the extensive amount of studies on the biology of PKCθ in mouse T cells, very little is known about its regulation and function in human T cells. This is a substantial gap that would need to be filled if PKCθ is destined to fulfill its promise as a clinically relevant drug target (Altman and Kong, 2012). As discussed earlier, the dependence of T cell-mediated deleterious autoimmune/inflammatory responses, including GvHD, on PKCθ, but its dispensable role in beneficial responses (antiviral immunity and GvL response) make it an attractive clinical drug target with potentially advantage over global immunosuppressive drugs such as calcineurin inhibitors (e.g., cyclosporine A), which have pronounced toxic side effects. Indeed, there has been considerable interest among pharmaceutical companies in developing small molecule selective PKCθ catalytic activity inhibitors, and AEB071,the most advanced of these compounds, which inhibits other PKC family members in addition to PKCθ, is currently in early clinical trials (Evenou et al., 2009).
Nevertheless, small molecule inhibitors of protein kinases often have toxic side effects because of their lack of absolute specificity, which reflects the relatively high conservation of catalytic domains within the protein kinase family, and even more so within the PKC family. Furthermore, since catalytic kinase inhibitors in current clinical use are ATP competitors, they need to be used at relatively high and potentially toxic concentrations in order to effectively compete with ATP, whose intracellular concentration is ~1 mM. As a result, there has recently been considerable interest and progress in developing allosteric kinase inhibitors, which bind to sites other than the catalytic site in kinases and, thus, are likely to be much more selective and less toxic (Lamba and Ghosh, 2012). Our recent study (Kong et al., 2011) demonstrates a new potential approach for attenuating PKCθ-dependent functions utilizing allosteric compounds based on the critical PR motif in the V3 domain of PKCθ that will block its Lck-mediated association with CD28 and recruitment to the IS, which is obligatory for its downstream signaling functions. This new approach could serve as a basis for the development of new therapeutic agents that would selectively suppress undesired T cell-mediated inflammation and autoimmunity or prevent graft rejection, while preserving desired immunity, such as antiviral responses.
Statements
Acknowledgments
This is manuscript number 1529 from the La Jolla Institute for Allergy and Immunology. Work in our laboratory is supported by the USA-Israel Binational Science Foundation, the Israel Science Foundation administered by the Israel Academy of Science and Humanities, and by NIH grant CA35299. Noah Isakov holds the Joseph H. Krupp Chair in Cancer Immunobiology.
Conflict of interest
The authors declare that the research was conducted in the absence of any com mercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AltmanA.KongK.-F. (2012). PKCθ: a new target for selective immunosuppression.Exp. Rev. Clin. Immunol.8205–208.
2
AndersonK.FitzgeraldM.DupontM.WangT.PazN.DorschM.HealyA.XuY.OcainT.SchopfL.JaffeeB.PicarellaD. (2006). Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases.Autoimmunity39469–478.
3
AndresP. G.HowlandK. C.NirulaA.KaneL. P.BarronL.DresnekD.SadraA.ImbodenJ.WeissA.AbbasA. K. (2004). Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation.Nat. Immunol.5435–442.
4
ApplemanL. J.BoussiotisV. A. (2003). T cell anergy and costimulation.Immunol. Rev.192161–180.
5
AugustA.DupontB. (1994). CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase.Int. Immunol.6769–774.
6
AugustA.GibsonS.KawakamiY.KawakamiT.MillsG. B.DupontB. (1994). CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line.Proc. Natl. Acad. Sci. U.S.A.919347–9351.
7
BaierG.TelfordD.GiampaL.CoggeshallK. M.Baier-BitterlichG.IsakovN.AltmanA. (1993). Molecular cloning and characterization of PKC theta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells.J. Biol. Chem.2684997–5004.
8
BaierG.WagnerJ. (2009). PKC inhibitors: potential in T cell-dependent immune diseases.Curr. Opin. Cell Biol.21262–267.
9
Baier-BitterlichG.UberallF.BauerB.FresserF.WachterH.GrunickeH.UtermannG.AltmanA.BaierG. (1996). Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes.Mol. Cell Biol.161842–1850.
10
BarberE. K.DasguptaJ. D.SchlossmanS. F.TrevillyanJ. M.RuddC. E. (1989). The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.Proc. Natl. Acad. Sci. U.S.A.863277–3281.
11
BauerB.KrumbockN.FresserF.HochholdingerF.SpitalerM.SimmA.UberallF.SchravenB.BaierG. (2001). Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells.J. Biol. Chem.27631627–31634.
12
BauerF.HofingerE.HoffmannS.RoschP.SchweimerK.StichtH. (2004). Characterization of Lck-binding elements in the herpesviral regulatory Tip protein.Biochemistry4314932–14939.
13
Berg-BrownN. N.GronskiM. A.JonesR. G.ElfordA. R.DeenickE. K.OdermattB.LittmanD. R.OhashiP. S. (2004). PKCtheta signals activation versus tolerance in vivo.J. Exp. Med.199743–752.
14
BerridgeM. J.IrvineR. F. (1984). Inositol trisphosphate, a novel second messenger in cellular signal transduction.Nature312315–321.
15
BertinJ.WangL.GuoY.JacobsonM. D.PoyetJ. L.SrinivasulaS. M.MerriamS.DiStefanoP. S.AlnemriE. S. (2001). CARD11 and CARD14 are novel caspase recruitment domain (CARD)/ membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.J. Biol. Chem.27611877–11882.
16
BoiseL. H.Gonzalez-GarciaM.PostemaC. E.DingL.LindstenT.TurkaL. A.MaoX.NunezG.ThompsonC. B. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.Cell74597–608.
17
BourguignonL. Y.IidaN.SobrinL.BourguignonG. J. (1994). Identification of an IP3 receptor in endothelial cells.J. Cell Physiol.15929–34.
18
ChangJ. D.XuY.RaychowdhuryM. K.WareJ. A. (1993). Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets.J. Biol. Chem.26814208–14214.
19
CheT.YouY.WangD.TannerM. J.DixitV. M.LinX. (2004). MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation.J. Biol. Chem.27915870–15876.
20
ChuangE.FisherT. S.MorganR. W.RobbinsM. D.DuerrJ. M.Vander HeidenM. G.GardnerJ. P.HamborJ. E.NeveuM. J.ThompsonC. B. (2000). The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.Immunity13313–322.
21
ChuangH. C.LanJ. L.ChenD. Y.YangC. Y.ChenY. M.LiJ. P.HuangC. Y.LiuP. E.WangX.TanT. H. (2011). The kinase GLK controls autoimmunity and NF-kappaB signaling by activating the kinase PKC-theta in T cells.Nat. Immunol.121113–1118.
22
CohenS.BraimanA.ShubinskyG.OhayonA.AltmanA.IsakovN. (2009). PKC-theta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion.Biochem. Biophys. Res. Commun.38522–27.
23
ComptonH. L.FarrellJ. P. (2002). CD28 costimulation and parasite dose combine to influence the susceptibility of BALB/c mice to infection with Leishmania major.J. Immunol.1681302–1308.
24
CoudronniereN.VillalbaM.EnglundN.AltmanA. (2000). NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta.Proc. Natl. Acad. Sci. U.S.A.973394–3399.
25
DiehnM.AlizadehA. A.RandoO. J.LiuC. L.StankunasK.BotsteinD.CrabtreeG. R.BrownP. O. (2002). Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation.Proc. Natl. Acad. Sci. U.S.A.9911796–11801.
26
DienzO.HehnerS. P.DrogeW.SchmitzM. L. (2000). Synergistic activation of NF-kappa B by functional cooperation between vav and PKCtheta in T lymphocytes.J. Biol. Chem.27524547–24551.
27
DodsonL. F.BoomerJ. S.DeppongC. M.ShahD. D.SimJ.BrickerT. L.RussellJ. H.GreenJ. M. (2009). Targeted knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation.Mol. Cell Biol.293710–3721.
28
DustinM. L.ChakrabortyA. K.ShawA. S. (2010). Understanding the structure and function of the immunological synapse.Cold Spring Harb. Perspect. Biol.2a002311.
29
DustinM. L.ShawA. S. (1999). Costimulation: building an immunological synapse.Science283649–650.
30
DustinM. L.ZhuC. (2006). T cells like a firm molecular handshake.Proc. Natl. Acad. Sci. U.S.A.1034335–4336.
31
DustinM. L. (2009). The cellular context of T cell signaling.Immunity30482–492.
32
EllisJ. H.AshmanC.BurdenM. N.KilpatrickK. E.MorseM. A.HamblinP. A. (2000). GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28.J. Immunol.1645805–5814.
33
EvenouJ. P.WagnerJ.ZenkeG.BrinkmannV.WagnerK.KovarikJ.WelzenbachK. A.Weitz-SchmidtG.GuntermannC.TowbinH.CottensS.KaminskiS.LetschkaT.Lutz-NicoladoniC.GruberT.Hermann-KleiterN.ThuilleN.BaierG. (2009). The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.J. Pharmacol. Exp. Ther.330792–801.
34
GaideO.FavierB.LeglerD. F.BonnetD.BrissoniB.ValituttiS.BronC.TschoppJ.ThomeM. (2002). CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation.Nat. Immunol.3836–843.
35
GarconF.GhiottoM.GerardA.YangW. C.OliveD.NunesJ. A. (2004). The SH3 domain of Tec kinase is essential for its targeting to activated CD28 costimulatory molecule.Eur. J. Immunol.341972–1980.
36
GiannoniF.LyonA. B.WareingM. D.DiasP. B.SarawarS. R. (2005). Protein kinase C theta is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68.J. Virol.796808–6813.
37
GibsonS.AugustA.BranchD.DupontB.MillsG. M. (1996). Functional LCK is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK.J. Biol. Chem.2717079–7083.
38
GibsonS.TruittK.LuY.LapushinR.KhanH.ImbodenJ. BMillsG. B. (1998). Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK.Biochem. J.3301123–1128.
39
GreenJ. M.NoelP. J.SperlingA. I.WalunasT. L.GrayG. S.BluestoneJ. A.ThompsonC. B. (1994). Absence of B7-dependent responses in CD28-deficient mice.Immunity1501–508.
40
GrossJ. A.St JohnT.AllisonJ. P. (1990). The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression.J. Immunol.1443201–3210.
41
GruberT.Hermann-KleiterN.Pfeifhofer-ObermairC.Lutz-NicoladoniC.ThuilleN.LetschkaT.BarsigJ.BaudlerM.LiJ.MetzlerB.Nusslein-HildesheimB.WagnerJ.LeitgesM.BaierG. (2009). PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo.Mol. Immunol.462071–2079.
42
GudmundsdottirH.WellsA. D.TurkaL. A. (1999). Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity.J. Immunol.1625212–5223.
43
GuptaS.ManicassamyS.VasuC.KumarA.ShangW.SunZ. (2008). Differential requirement of PKC-theta in the development and function of natural regulatory T cells.Mol. Immunol.46213–224.
44
HaraH.BakalC.WadaT.BouchardD.RottapelR.SaitoT.PenningerJ. M. (2004). The molecular adapter Carma1 controls entry of IkappaB kinase into the central immune synapse.J. Exp. Med.2001167–1177.
45
HaraH.WadaT.BakalC.KozieradzkiI.SuzukiS.SuzukiN.NghiemM.GriffithsE. K.KrawczykC.BauerB.D’AcquistoF.GhoshS.YehW. C.BaierG.RottapelR.PenningerJ. M. (2003). The MAGUK family protein CARD11 is essential for lymphocyte activation.Immunity18763–775.
46
HaradaY.TanabeE.WatanabeR.WeissB. D.MatsumotoA.ArigaH.KoiwaiO.FukuiY.KuboM.JuneC. H.AbeR. (2001). Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation.J. Biol. Chem.2769003–9008.
47
HardingF. A.McArthurJ. G.GrossJ. A.RauletD. H.AllisonJ. P. (1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.Nature356607–609.
48
HarhajE. W.SunS. C. (1998). IkappaB kinases serve as a target of CD28 signaling.J. Biol. Chem.27325185–25190.
49
HealyA. M.IzmailovaE.FitzgeraldM.WalkerR.HattersleyM.SilvaM.SiebertE.TerkelsenJ.PicarellaD.PickardM. D.LeClairB.ChandraS.JaffeeB. (2006). PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.J. Immunol.1771886–1893.
50
HoC.SlaterS. J.StaglianoB.StubbsC. D. (2001). The C1 domain of protein kinase C as a lipid bilayer surface sensing module.Biochemistry4010334–10341.
51
HofingerE.StichtH. (2005). Multiple modes of interaction between Lck and CD28.J. Immunol.1743839–3840; author reply 3840.
52
HoldorfA. D.GreenJ. M.LevinS. D.DennyM. F.StrausD. B.LinkV.ChangelianP. S.AllenP. M.ShawA. S. (1999). Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation.J. Exp. Med.190375–384.
53
HoldorfA. D.LeeK. H.BurackW. R.AllenP. M.ShawA. S. (2002). Regulation of Lck activity by CD4 and CD28 in the immunological synapse.Nat. Immunol.3259–264.
54
HuangJ.LoP. F.ZalT.GascoigneN. R.SmithB. A.LevinS. D.GreyH. M. (2002). CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse.Proc. Natl. Acad. Sci. U.S.A.999369–9373.
55
HurleyJ. H.NewtonA. C.ParkerP. J.BlumbergP. M.NishizukaY. (1997). Taxonomy and function of C1 protein kinase C homology domains.Protein Sci.6477–480.
56
HutchcroftJ. E.BiererB. E. (1994). Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins.Proc. Natl. Acad. Sci. U.S.A.913260–3264.
57
InoueM.KishimotoA.TakaiY.NishizukaY. (1977). Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain.J. Biol. Chem.2527610–7616.
58
IsakovN.AltmanA. (1985). Tumor promoters in conjunction with calcium ionophores mimic antigenic stimulation by reactivation of alloantigen-primed murine T lymphocytes.J. Immunol.1353674–3680.
59
IsakovN.AltmanA. (1987). Human T lymphocyte activation by tumor promoters: role of protein kinase C.J. Immunol.1383100–3107.
60
IsakovN.AltmanA. (2002). Protein kinase C-theta in T cell activation.Annu. Rev. Immunol.20761–794.
61
IsakovN.MallyM. I.ScholzW.AltmanA. (1987). T-lymphocyte activation: the role of protein kinase C and the bifurcating inositol phospholipid signal transduction pathway.Immunol. Rev.9589–111.
62
JacobsM. D.HarrisonS. C. (1998). Structure of an IkappaBalpha/NF-kappaB complex.Cell95749–758.
63
JainJ.LohC.RaoA. (1995). Transcriptional regulation of the IL-2 gene.Curr. Opin. Immunol.7333–342.
64
JangM. S.PanF.EricksonL. M.FisnikuO.CrewsG.WynnC.HongI. C.TamuraK.KobayashiM.JiangH. (2008). A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway.Transplantation851051–1055.
65
JohnsonJ. E.GiorgioneJ.NewtonA. C. (2000). The C1 and C2 domains of protein kinase C are independent membrane targeting modules, with specificity for phosphatidylserine conferred by the C1 domain.Biochemistry3911360–11369.
66
KarinM. (1999). How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex.Oncogene186867–6874.
67
KarivI.TrunehA.SweetR. W. (1996). Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function.J. Immunol.15729–38.
68
KhanA. A.SteinerJ. P.KleinM. G.SchneiderM. F.SnyderS. H. (1992). IP3 receptor: localization to plasma membrane of T cells and cocapping with the T cell receptor.Science257815–818.
69
KhoshnanA.BaeD.TindellC. A.NelA. E. (2000). The physical association of protein kinase C theta with a lipid raft-associated inhibitor of kappa B factor kinase (IKK) complex plays a role in the activation of the NF-kappa B cascade by TCR and CD28.J. Immunol.1656933–6940.
70
KingC. L.XianliJ.JuneC. H.AbeR.LeeK. P. (1996). CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection.Eur. J. Immunol.262448–2455.
71
KingP. D.SadraA.TengJ. M.Xiao-RongL.HanA.SelvakumarA.AugustA.DupontB. (1997). Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK.J. Immunol.158580–590.
72
KishimotoA.TakaiY.MoriT.KikkawaU.NishizukaY. (1980). Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover.J. Biol. Chem.2552273–2276.
73
KondoS.KoosheshF.WangB.FujisawaH.SauderD. N. (1996). Contribution of the CD28 molecule to allergic and irritant-induced skin reactions in CD28-/- mice.J. Immunol.1574822–4829.
74
KongK. F.YokosukaT.Canonigo-BalancioA. J.IsakovN.SaitoT.AltmanA. (2011). A novel motif in the V3 domain of protein kinase C-theta (PKC-theta) determines its immunological synapse localization and functions in T cells via association with CD28.Nat. Immunol.1105–1112.
75
KrinzmanS. J.De SanctisG. T.CernadasM.MarkD.WangY.ListmanJ.KobzikL.DonovanC.NassrK.KatonaI.ChristianiD. C.PerkinsD. L.FinnP. W. (1996). Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model.J. Clin. Invest.982693–2699.
76
KwonM. J.MaJ.DingY.WangR.SunZ. (2012). Protein kinase C-theta promotes Th17 differentiation via upregulation of Stat3.J. Immunol.1885887–5897.
77
LambaV.GhoshI. (2012). New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.Curr. Pharm. Des.182936–2945.
78
LiC. R.BergL. J. (2005). Itk is not essential for CD28 signaling in naive T cells.J. Immunol.1744475–4479.
79
LiY.HuJ.VitaR.SunB.TabataH.AltmanA. (2004). SPAK kinase is a substrate and target of PKCtheta in T-cell receptor-induced AP-1 activation pathway.EMBO J.231112–1122.
80
LiaoX. C.FournierS.KilleenN.WeissA.AllisonJ. P.LittmanD. R. (1997). Itk negatively regulates induction of T cell proliferation by CD28 costimulation.J. Exp. Med.186221–228.
81
LinX.O’MahonyA.MuY.GeleziunasR.GreeneW. C. (2000). Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta.Mol. Cell Biol.202933–2940.
82
LinsleyP. S.NadlerS. G. (2009). The clinical utility of inhibiting CD28-mediated costimulation.Immunol. Rev.229307–321.
83
LiuY.LiuY. C.MellerN.GiampaL.EllyC.DoyleM.AltmanA. (1999). Protein kinase C activation inhibits tyrosine phosphorylation of Cbl and its recruitment of Src homology 2 domain-containing proteins.J. Immunol.1627095–7101.
84
LiuY.WitteS.LiuY. C.DoyleM.EllyC.AltmanA. (2000). Regulation of protein kinase Ctheta function during T cell activation by Lck-mediated tyrosine phosphorylation.J. Biol. Chem.2753603–3609.
85
LorenzoP. S.BeheshtiM.PettitG. R.StoneJ. C.BlumbergP. M. (2000). The guanine nucleotide exchange factor RasGRP is a high -affinity target for diacylglycerol and phorbol esters.Mol. Pharmacol.57840–846.
86
LucasP. J.NegishiI.NakayamaK.FieldsL. E.LohD. Y. (1995). Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response.J. Immunol.1545757–5768.
87
LyakhL.GhoshP.RiceN. R. (1997). Expression of NFAT-family proteins in normal human T cells.Mol. Cell Biol.172475–2484.
88
MacianF.ImS. H.Garcia-CozarF. J.RaoA. (2004). T-cell anergy.Curr. Opin. Immunol.16209–216.
89
ManicassamyS.YinD.ZhangZ.MolineroL. L.AlegreM. L.SunZ. (2008). A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection.J. Immunol.181513–520.
90
MarengereL. E.OkkenhaugK.ClavreulA.CouezD.GibsonS.MillsG. B.MakT. W.RottapelR. (1997). The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28.J. Immunol.1593220–3229.
91
MarslandB. J.NembriniC.GrunK.ReissmannR.KurrerM.LeipnerC.KopfM. (2007). TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis.J. Immunol.1783466–3473.
92
MarslandB. J.NembriniC.SchmitzN.AbelB.KrautwaldS.BachmannM. F.KopfM. (2005). Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses.Proc. Natl. Acad. Sci. U.S.A.10214374–14379.
93
MarslandB. J.SoosT. J.SpathG.LittmanD. R.KopfM. (2004). Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses.J. Exp. Med.200181–189.
94
MatsumotoR.WangD.BlonskaM.LiH.KobayashiM.PappuB.ChenY.WangD.LinX. (2005). Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation.Immunity23575–585.
95
McAllister-LucasL. M.InoharaN.LucasP. C.RulandJ.BenitoA.LiQ.ChenS.ChenF. F.YamaokaS.VermaI. M.MakT. W.NunezG. (2001). Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction.J. Biol. Chem.27630589–30597.
96
MellerN.AltmanA.IsakovN. (1998). New perspectives on PKC-theta, a member of the novel subfamily of protein kinase C.Stem Cells16178–192.
97
MellerN.ElitzurY.IsakovN. (1999). Protein kinase C-theta distribution analysis in hematopoietic cells: proliferating T cells exhibit high proportions of PKC-theta in the particulate fraction.Cell Immunol.193185–193.
98
MellerN.LiuY. C.CollinsT. L.Bonnefoy-BerardN.BaierG.IsakovN.AltmanA. (1996). Direct interaction between protein kinase C theta (PKC theta) and 14-3-3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function.Mol. Cell Biol.165782–5791.
99
MellorH.ParkerP. J. (1998). The extended protein kinase C superfamily.Biochem. J.332281–292.
100
MercurioF.ZhuH.MurrayB. W.ShevchenkoA.BennettB. L.LiJ.YoungD. B.BarbosaM.MannM.ManningA.RaoA. (1997). IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.Science278860–866.
101
MichelF.ManginoG.Attal-BonnefoyG.TuostoL.AlcoverA.RoumierA.OliveD.AcutoO. (2000). CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation.J. Immunol.1653820–3829.
102
MillerJ.BakerC.CookK.GrafB.Sanchez-LockhartM.SharpK.WangX.YangB.YoshidaT. (2009). Two pathways of costimulation through CD28.Immunol. Res.45159–172.
103
MittruckerH. W.KursarM.KohlerA.HurwitzR.KaufmannS. H. (2001). Role of CD28 for the generation and expansion of antigen-specific CD8(+) T lymphocytes during infection with Listeria monocytogenes.J. Immunol.1675620–5627.
104
MonksC. R.FreibergB. A.KupferH.SciakyN.KupferA. (1998). Three-dimensional segregation of supramolecular activation clusters in T cells.Nature39582–86.
105
MonksC. R.KupferH.TamirI.BarlowA.KupferA. (1997). Selective modulation of protein kinase C-theta during T-cell activation.Nature38583–86.
106
NalefskiE. A.FalkeJ. J. (1996). The C2 domain calcium-binding motif: structural and functional diversity.Protein Sci.52375–2390.
107
NewtonA. C. (1995). Protein kinase C: structure, function, and regulation.J. Biol. Chem.27028495–28498.
108
NishizukaY. (1984). Turnover of inositol phospholipids and signal transduction.Science2251365–1370.
109
OhayonA.DongG.IsakovN. (2007). “Involvement of PKCθ in CD4+ T cell polarization and mouse resistance to cutaneous Leishmaniasis,” inLymphocyte Activation and Signal Transduction,ed.IsakovN.(Trivandrum:Transworld Research Network)221–238.
110
OkkenhaugK.RottapelR. (1998). Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction.J. Biol. Chem.27321194–21202.
111
OsadaS.MizunoK.SaidoT. C.SuzukiK.KurokiT.OhnoS. (1992). A new member of the protein kinase C family, nPKC theta, predominantly expressed in skeletal muscle.Mol. Cell Biol.123930–3938.
112
PagesF.RagueneauM.RottapelR.TrunehA.NunesJ.ImbertJ.OliveD. (1994). Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling.Nature369327–329.
113
PaigeL. A.NadlerM. J.HarrisonM. L.CassadyJ. M.GeahlenR. L. (1993). Reversible palmitoylation of the protein-tyrosine kinase p56lck.J. Biol. Chem.2688669–8674.
114
PfeifhoferC.KoflerK.GruberT.TabriziN. G.LutzC.MalyK.LeitgesM.BaierG. (2003). Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells.J. Exp. Med.1971525–1535.
115
Pfeifhofer-ObermairC.ThuilleN.BaierG. (2012). Involvement of distinct PKC gene products in T cell functions.Front. Immun.3:22010.3389/fimmu.2012.00220
116
PietromonacoS. F.SimonsP. C.AltmanA.EliasL. (1998). Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence.J. Biol. Chem.2737594–7603.
117
PrasadK. V.CaiY. C.RaabM.DuckworthB.CantleyL.ShoelsonS. E.RuddC. E. (1994). T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif.Proc. Natl. Acad. Sci. U.S.A.912834–2838.
118
RaabM.CaiY. C.BunnellS. C.HeyeckS. D.BergL. J.RuddC. E. (1995). p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.Proc. Natl. Acad. Sci. U.S.A.928891–8895.
119
RegnierC. H.SongH. Y.GaoX.GoeddelD. V.CaoZ.RotheM. (1997). Identification and characterization of an IkappaB kinase.Cell90373–383.
120
ReichertP.ReinhardtR. L.IngulliE.JenkinsM. K. (2001). Cutting edge: in vivo identification of TCR redistribution and polarized IL-2 production by naive CD4 T cells.J. Immunol.1664278–4281.
121
RibotJ. C.debarrosA.Silva-SantosB. (2011). Searching for “signal 2”: costimulation requirements of gamma/delta T cells.Cell. Mol. Life Sci.682345–2355.
122
RinconM.FlavellR. A. (1994). AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes.EMBO J.134370–4381.
123
RonD.NapolitanoE. W.VoronovaA.VasquezN. J.RobertsD. N.CalioB. L.CaothienR. H.PettifordS. M.WellikS.MandacJ. B.KauvarL. M. (1999). Direct interaction in T-cells between thetaPKC and the tyrosine kinase p59fyn.J. Biol. Chem.27419003–19010.
124
RosseC.LinchM.KermorgantS.CameronA. J.BoeckelerK.ParkerP. J. (2010). PKC and the control of localized signal dynamics.Nat. Rev. Mol. Cell Biol.11103–112.
125
RuddC. E.AndersonP.MorimotoC.StreuliM.SchlossmanS. F. (1989). Molecular interactions, T-cell subsets and a role of the CD4/CD8:p56lck complex in human T-cell activation.Immunol. Rev.111225–266.
126
RuddC. E.TrevillyanJ. M.DasguptaJ. D.WongL. L.SchlossmanS. F. (1988). The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes.Proc. Natl. Acad. Sci. U.S.A.855190–5194.
127
Ruefli-BrasseA. A.FrenchD. M.DixitV. M. (2003). Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase.Science3021581–1584.
128
RulandJ.DuncanG. S.EliaA.del Barco BarrantesI.NguyenL.PlyteS.MillarD. G.BouchardD.WakehamA.OhashiP. S.MakT. W. (2001). Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure.Cell10433–42.
129
RulandJ.DuncanG. S.WakehamA.MakT. W. (2003). Differential requirement for Malt1 in T and B cell antigen receptor signaling.Immunity19749–758.
130
RulifsonI. C.SperlingA. I.FieldsP. E.FitchF. W.BluestoneJ. A. (1997). CD28 costimulation promotes the production of Th2 cytokines.J. Immunol.158658–665.
131
SadraA.CinekT.ArellanoJ. L.ShiJ.TruittK. E.ImbodenJ. B. (1999). Identification of tyrosine phosphorylation sites in the CD28 cytoplasmic domain and their role in the costimulation of Jurkat T cells.J. Immunol.1621966–1973.
132
Salek-ArdakaniS.SoT.HaltemanB. S.AltmanA.CroftM. (2004). Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase C theta.J. Immunol.1736440–6447.
133
Salek-ArdakaniS.SoT.HaltemanB. S.AltmanA.CroftM. (2005). Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis.J. Immunol.1757635–7641.
134
SalomonB.BluestoneJ. A. (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.Annu. Rev. Immunol.19225–252.
135
Sanchez-LockhartM.MarinE.GrafB.AbeR.HaradaY.SedwickC. E.MillerJ. (2004). Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways.J. Immunol.1737120–7124.
136
Schmidt-SupprianM.TianJ.GrantE. P.PasparakisM.MaehrR.OvaaH.PloeghH. L.CoyleA. J.RajewskyK. (2004). Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation.Proc. Natl. Acad. Sci. U.S.A.1014566–4571.
137
SchneiderH.CaiY. C.PrasadK. V.ShoelsonS. E.RuddC. E. (1995). T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras.Eur. J. Immunol.251044–1050.
138
SchweitzerA. N.BorrielloF.WongR. C.AbbasA. K.SharpeA. H. (1997). Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86.J. Immunol.1582713–2722.
139
ShahinianA.PfefferK.LeeK. P.KundigT. M.KishiharaK.WakehamA.KawaiK.OhashiP. S.ThompsonC. B.MakT. W. (1993). Differential T cell costimulatory requirements in CD28-deficient mice.Science261609–612.
140
SmithB. L.KrushelnyckyB. W.Mochly-RosenD.BergP. (1996). The HIV nef protein associates with protein kinase C theta.J. Biol. Chem.27116753–16757.
141
SommerK.GuoB.PomerantzJ. L.BandaranayakeA. D.Moreno-GarciaM. E.OvechkinaY. L.RawlingsD. J. (2005). Phosphorylation of the CARMA1 linker controls NF-kappaB activation.Immunity23561–574.
142
SongyangZ.ShoelsonS. E.ChaudhuriM.GishG.PawsonT.HaserW. G.KingF.RobertsT.RatnofskyS.LechleiderR. J.NeelB. G.BirgeR. B.FajardoJ. E.ChouM. M.HanafusaH.SchaffhausenB.CantleyL. C. (1993). SH2 domains recognize specific phosphopeptide sequences.Cell72767–778.
143
SuB.JacintoE.HibiM.KallunkiT.KarinM.Ben-NeriahY. (1994). JNK is involved in signal integration during costimulation of T lymphocytes.Cell77727–736.
144
SunZ.ArendtC. W.EllmeierW.SchaefferE. M.SunshineM. J.GandhiL.AnnesJ.PetrzilkaD.KupferA.SchwartzbergP. L.LittmanD. R. (2000). PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes.Nature404402–407.
145
SutcliffeE. L.BuntingK. L.HeY. Q.LiJ.PhetsouphanhC.SeddikiN.ZafarA.HindmarshE. J.ParishC. R.KelleherA. D.McInnesR. L.TayaT.MilburnP. J.RaoS. (2011). Chromatin-associated protein kinase C-theta regulates an inducible gene expression program and microRNAs in human T lymphocytes.Mol. Cell41704–719.
146
TakaiY.KishimotoA.IwasaY.KawaharaY.MoriT.NishizukaY. (1979). Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids.J. Biol. Chem.2543692–3695.
147
TakedaK.HaradaY.WatanabeR.InutakeY.OgawaS.OnukiK.KagayaS.TanabeK.KishimotoH.AbeR. (2008). CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis.Int. Immunol.201507–1515.
148
TanS. L.ZhaoJ.BiC.ChenX. C.HepburnD. L.WangJ.SedgwickJ. D.ChintalacharuvuS. R.NaS. (2006). Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice.J. Immunol.1762872–2879.
149
TavanoR.ContentoR. L.BarandaS. J.SoligoM.TuostoL.ManesS.ViolaA. (2006). CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse.Nat. Cell Biol.81270–1276.
150
TavanoR.GriG.MolonB.MarinariB.RuddC. E.TuostoL.ViolaA. (2004). CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes.J. Immunol.1735392–5397.
151
TengJ. M.KingP. D.SadraA.LiuX.HanA.SelvakumarA.AugustA.DupontB. (1996). Phosphorylation of each of the distal three tyrosines of the CD28 cytoplasmic tail is required for CD28-induced T cell IL-2 secretion.Tissue Antigens48255–264.
152
ThompsonC. B.LindstenT.LedbetterJ. A.KunkelS. L.YoungH. A.EmersonS. G.LeidenJ. M.JuneC. H. (1989). CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.Proc. Natl. Acad. Sci. U.S.A.861333–1337.
153
TruittK. E.HicksC. M.ImbodenJ. B. (1994). Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells.J. Exp. Med.1791071–1076.
154
TrunehA.AlbertF.GolsteinP.Schmitt-VerhulstA. M. (1985). Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester.Nature313318–320.
155
TrunehA.ReddyM.RyanP.LynS. D.EichmanC.CouezD.HurleM. R.SekalyR. P.OliveD.SweetR. (1996). Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.Mol. Immunol.33321–334.
156
TsengS. Y.WaiteJ. C.LiuM.VardhanaS.DustinM. L. (2008). T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C theta.J. Immunol.1814852–4863.
157
ValenzuelaJ. O.IclozanC.HossainM. S.PrlicM.HopewellE.BronkC. C.WangJ.CelisE.EngelmanR. W.BlazarB. R.BevanM. J.WallerE. K.YuX. Z.BegA. A. (2009). PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.J. Clin. Invest.1193774–3786.
158
VallejoA. N. (2005). CD28 extinction in human T cells: altered functions and the program of T-cell senescence.Immunol. Rev.205158–169.
159
VardhanaS.ChoudhuriK.VarmaR.DustinM. L. (2010). Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster.Immunity32531–540.
160
VeilletteA.BookmanM. A.HorakE. M.BolenJ. B. (1988). The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck.Cell55301–308.
161
ViaC. S.RusV.NguyenP.LinsleyP.GauseW. C. (1996). Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.J. Immunol.1574258–4267.
162
ViolaA.SchroederS.SakakibaraY.LanzavecchiaA. (1999). T lymphocyte costimulation mediated by reorganization of membrane microdomains.Science283680–682.
163
WitteS.VillalbaM.BiK.LiuY.IsakovN.AltmanA. (2000). Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain.J. Biol. Chem.2751902–1909.
164
WulfingC.DavisM. M. (1998). A receptor/cytoskeletal movement triggered by costimulation during T cell activation.Science2822266–2269.
165
XueL.MorrisS. W.OrihuelaC.TuomanenE.CuiX.WenR.WangD. (2003). Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells.Nat. Immunol.4857–865.
166
YangW. C.OliveD. (1999). Tec kinase is involved in transcriptional regulation of IL-2 and IL-4 in the CD28 pathway.Eur. J. Immunol.291842–1849.
167
YokosukaT.KobayashiW.Sakata-SogawaK.TakamatsuM.Hashimoto-TaneA.DustinM. L.TokunagaM.SaitoT. (2008). Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation.Immunity29589–601.
168
YokosukaT.KobayashiW.TakamatsuM.Sakata-SogawaK.ZengH.Hashimoto-TaneA.YagitaH.TokunagaM.SaitoT. (2010). Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation.Immunity33326–339.
169
YokosukaT.Sakata-SogawaK.KobayashiW.HiroshimaM.Hashimoto-TaneA.TokunagaM.DustinM. L.SaitoT. (2005). Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76.Nat Immunol61253–1262.
170
Zanin-ZhorovA.DingY.KumariS.AtturM.HippenK. L.BrownM.BlazarB. R.AbramsonS. B.LafailleJ. J.DustinM. L. (2010). Protein kinase C-theta mediates negative feedback on regulatory T cell function.Science328372–376.
171
Zanin-ZhorovA.DustinM. L.BlazarB. R. (2011). PKC-theta function at the immunological synapse: prospects for therapeutic targeting.Trends Immunol.32358–363.
172
zur HausenJ. D.BurnP.AmreinK. E. (1997). Co-localization of Fyn with CD3 complex, CD45 or CD28 depends on different mechanisms.Eur. J. Immunol.272643–2649.
Summary
Keywords
protein kinase C-theta, PKCθ, CD28, Lck, signal transduction, costimulation
Citation
Isakov N and Altman A (2012) PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors. Front. Immun. 3:273. doi: 10.3389/fimmu.2012.00273
Received
09 July 2012
Accepted
09 August 2012
Published
22 August 2012
Volume
3 - 2012
Edited by
Nick Gascoigne, Scripps Research Institute, USA
Reviewed by
Balbino Alarcon, Consejo Superior de Investigaciones Cientificas, Spain Salvatore Valitutti, INSERM, France
Copyright
© Isakov and Altman.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Noah Isakov, The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and the Cancer Research Center, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 84105, Israel. e-mail: noah@bgu.ac.il
This article was submitted to Frontiers in T Cell Biology, a specialty of Frontiers in Immunology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.